Using small molecules to define new targets for the treatment of disease
Matthew graduated from North Carolina State University in 2016 with his B.S. in Chemistry. As an undergraduate, he worked with Dr. Joshua Pierce on the total synthesis of alotamide A with applications to chemical probes for neurological disease. Further, Matthew conducted a summer research fellowship at Memorial Sloan Kettering Cancer Center under the direction of Dr. Derek Tan, in which he focused on the development of a synthetic method towards benzannulated medium-sized ring scaffolds. Matthew joined the Hergenrother lab in December of 2016 as a NIH Chemistry-Biology Interface fellow and Roger Adams Fellow. His work is focused on the synthesis and discovery of novel mutation-specific cancer therapeutics.
Overcoming resistance to targeted anticancer therapies through small-molecule mediated MEK degradation
Peh, J.; Boudreau, M. W.; Smith, H. M.; and Hergenrother, P. J.
Cell Chem. Biol.2018, published on web June 14, 2018.